Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Congress 2024

ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition

Welcome and introduction

Date

14 Sep 2024

Session

ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition

Presenters

Joyce O'Shaughnessy

Authors

J. O'Shaughnessy

Author affiliations

  • Texas Oncology - Baylor Sammons Cancer Center, 75246 - Dallas/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition

Resources:

Webcast

Concluding remarks

Presenter: Cristina Saura Manich

Session: ESMO Colloquium supported by Eli Lilly and Company - Hormone-receptor (+), HER2 (-) advanced breast cancer: The biology and treatment landscape post-progression after CDK4/6 inhibition

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.